When to choose peptides vs traditional approaches — the meta-decision framework
9 min read · Uplevel editorial
You've been reading about peptides long enough that you've started wondering whether you're looking at a legitimate part of modern medicine or a sophisticated version of the supplement industry's tendency to package hope in molecular language. That skepticism is healthy. It's also incomplete. The honest answer is that peptides occupy a real but specifically bounded place in the clinical landscape, and the question isn't whether they belong there — they do — but when they're the right tool and when something else is.
That question has a structure. Working through it matters before you decide anything.
Start with the category of problem you're trying to address, because the first branching decision point is whether this is a serious medical condition or a preventive and wellness context. The distinction carries different implications for where peptides belong in the framework.
If you have a serious medical condition — hypertension, type 2 diabetes, cardiovascular disease meeting statin criteria, a mood disorder requiring pharmacological management, an autoimmune condition — the standard of care exists because it has been evaluated in large randomized controlled trials, and it works. The evidence behind lisinopril for hypertension, statins for cardiovascular risk reduction, metformin for type 2 diabetes management, and SSRIs for major depression is not modest. It's the most rigorous evidence category in medicine. In these contexts, peptides — with their generally earlier-stage evidence bases and less-established clinical profiles — belong as adjunctive considerations, if at all, and not as primary treatments that replace the standard of care. Using BPC-157 instead of addressing a herniated disc with appropriate spine care, or using Selank instead of treating a clinical anxiety disorder with evidence-based approaches, is a category error that has real consequences for people who have conditions that are treatable with what we know works.
This framing is not an argument against peptides. It's an argument for proper placement. Adjunctive use — adding a researched peptide to a management plan that already includes appropriate conventional treatment — is different from substitution. And the difference matters clinically.
Now consider the contexts where peptides aren't adjunctive — where they are, in fact, the conventional treatment. GLP-1 receptor agonists, semaglutide and tirzepatide, are peptide drugs. They're FDA-approved, well-studied in large trials, and currently the standard of care for type 2 diabetes and obesity management in appropriate candidates. When your prescribing provider recommends semaglutide for weight management or glycemic control, they're recommending a peptide — not a peripheral option, not a novel experiment, but the evidence-based standard treatment. Growth hormone — and by extension, FDA-approved GH-related treatments for documented GH deficiency — is peptide-based medicine with an established place in clinical practice. Insulin is a peptide. Oxytocin is a peptide. The medical mainstream is full of peptide pharmacology that has been through the full regulatory evaluation process.
The practical question for most people reading about peptides in wellness and longevity contexts is not about the approved peptides, which are managed through standard prescribing channels. It's about the research-context and compounded peptides — Sermorelin, Ipamorelin, BPC-157, TB-500, MOTS-c, Selank, Semax, and the others — that exist outside the standard FDA approval pathway. These are real compounds with real mechanisms, studied in real research, and available through licensed compounding pharmacies with prescriptions from providers working in this space. They're not approved drugs. They're not supplements. They're somewhere in between, and understanding what that means for how you evaluate them is important.
The evidence-quality framework for this category should work as follows. Ask, for your specific use case: what is the best evidence supporting the peptide I'm considering, and how does that compare to the best evidence for the conventional alternative? The comparison has to be honest in both directions. Sometimes the conventional alternative has overwhelming evidence — decades of randomized controlled trials, established monitoring protocols, known side effects — and the peptide has preclinical research and case series. In that situation, the conventional treatment is likely the starting point and the peptide, if appropriate at all, is an adjunct. Sometimes the conventional alternative is a generic with known limitations that many patients don't tolerate well, and the peptide has a coherent mechanism and a meaningful body of research that points in the same direction. That comparison looks different. The evidence quality hierarchy — large randomized controlled trials at the top, preclinical and observational research below — applies to conventional treatments too; not every "conventional" approach has the same evidence quality.
The cost-effectiveness question deserves honesty that it rarely gets in this space. Compounded peptides are generally more expensive than generic pharmaceuticals. A month of metformin costs a few dollars. A month of MOTS-c costs considerably more. If the evidence for MOTS-c and metformin for AMPK activation is roughly comparable at the current state of research — and in human clinical data, metformin has substantially more — then the differential in cost requires a corresponding differential in expected benefit to justify it. This doesn't mean peptides are never worth the cost. It means the calculation should be explicit rather than assumed. Novelty is not the same as superiority, and the marketing layer in the peptide space leans heavily on novelty.
The integration framework is where the meta-decision becomes practical. For almost every situation where peptides are worth considering, foundational interventions are the prerequisite rather than the alternative. Consistent resistance training and appropriate recovery is a more powerful body composition intervention than any peptide protocol in a person who isn't training. Adequate sleep — not medicated sleep, structural sleep — is a more powerful recovery and cognitive health intervention than any compound that tries to compensate for its absence. Glycemic management through diet is a more powerful metabolic intervention than most peptides in someone who is eating in ways that continuously drive insulin resistance. The peptide conversation that starts with "I've got the foundations solid and I'm asking what might be an appropriate addition" is a coherent conversation. The one that starts with "the foundations aren't there and I'm hoping this will compensate" is one that rarely ends with the result you want.
The specialist evaluation framework rounds out the picture. Most of the decisions in this space — which peptide is appropriate, what dose, what duration, what monitoring, what interactions to consider — require clinical judgment based on your specific biology, not general principles that can be applied universally. A prescribing provider who works in this space brings the clinical picture: your labs, your history, your other medications, your actual complaint. The difference between a GH-axis peptide protocol that's useful for you and one that isn't depends on whether your slow-wave sleep is actually degraded, what your IGF-1 level looks like at baseline, whether you have any contraindications in your history. That's not information a general framework can substitute for. It's information that requires evaluation.
What this means for the decision you're trying to make: peptides have a legitimate and real place in modern healthcare. They're not fringe. They're not pseudoscience. Some of them have research bases that are genuinely interesting and mechanisms that are well-characterized. Some of them are actually FDA-approved drugs that are the standard of care for what you have. And some of them are research-context compounds available through compounding channels with evidence that's promising but incomplete, and that belong in a clinical conversation rather than a self-directed stack.
The meta-framework is this: know what category your situation falls into. If you have a diagnosable condition with a standard of care, start there. If you're in a preventive and optimization context with solid foundations in place, the peptide conversation is appropriate and potentially productive. Ask what the evidence quality comparison actually looks like between what you're considering and the alternatives. Apply cost-benefit thinking honestly. Work with a provider who can evaluate your specific picture rather than a general principle. Treat peptides as one tool in a toolkit that includes lifestyle, conventional pharmacology, and clinical judgment — not as a special category that bypasses the rest of the toolkit.
The person who ends up getting genuine value from a thoughtful peptide protocol is usually the one who arrived at it through that sequence: foundations solid, conventional options appropriately considered and either in use or ruled out with reasoning, and a specific purpose that the peptide addresses that other things don't. That person is not choosing peptides instead of medicine. They're using medicine, fully, including the parts of it that sit outside the conventional pharmacy.
That's what the framework is for.
Frequently asked